Trastuzumab treatment in breast cancer [5]

New England Journal of Medicine

Volumn 354, Issue 20, 2006, Pages 2186-

  Montemurro, Filippo ^a   Valabrega, Giorgio ^a   Aglietta, Massimo ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; NAVELBINE; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; BODY SURFACE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; FOLLOW UP; HUMAN; LETTER; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; GENES, ERBB-2; HUMANS;

EID: 33646676734     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc060852     Document Type: Letter

References (3)

1. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20.
2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
3. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.